Insights on the AAV Vector Global Market to 2035 – Adeno-Associated Viral Vectors Have Emerged as One of the Most Efficient Viral Vectors – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “AAV Vector Market: Focus on Drugs, Manufacturers and Technologies by Type of Therapy, Type of Gene Delivery Method Used, Target Therapeutic Area, Application Area, Scale of Operation and Geographical Regions: Industry Trends and Global Forecasts, 2022-2035” report has been added to ResearchAndMarkets.com’s offering.

This report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution and future opportunities associated with the adeno-associated viral vector market. The study underlines an in-depth analysis, highlighting the key drivers and the market trends related to this evolving segment of the pharmaceutical industry.

Given the potential of gene therapies in targeting the underlying cause of a disease at cellular level, the demand for such therapies has increased considerably over the past few years. Currently, more than 285 gene therapies are being evaluated in different phases of clinical development.

Further, various gene therapy developers have raised more than USD 10 billion capital during the year 2021. With the growing interest in such therapies, the demand for novel delivery vectors has also increased. Among various gene delivery vectors available, adeno-associated viral (AAV) vectors have emerged as one of the most efficient viral vectors. Till now, the USFDA has approved two adeno-associated viral vectors based drugs, LUXTURNA and ZOLGENSMA.

A number of adeno-associated viral vector-based therapies are also being evaluated in different clinical trials. In fact, it has been observed that clinical trials evaluating adeno-associated viral vector based therapies have increased at ~30% growth rate over the last few years. Further, it is worth mentioning that over 50 trials are expected to complete in the next three years.

In order to cater to the demand, close to 100 players, across the globe, have emerged for the development and manufacturing of adeno-associated viral vectors.

In fact, a number of these companies also offer advanced technology platforms, enabling the processing of adeno-associated viral vectors and related therapies across different scales of operation. Various industry and non-industry players are actively engaged in research and development of novel gene delivery technologies, which are safe and effective. This is evident from the patents filed for protection of intellectual property related to such technologies.

Additionally, multiple partnerships and collaborations have been established between the stakeholders in order to enhance development activity in this industry. Considering the prevalent trends and projected opportunity associated with the overall adeno-associated viral vector / AAV vector domain, we believe that the market is anticipated to witness substantial growth in the foreseen future.

Key Questions Answered

• Which adeno-associated viral vector-based therapy candidates are present in the current development pipeline? Which disease indications are targeted by such products?
• Who are the leading players (contract service providers and in-house manufacturers) engaged in the development of adeno-associated viral vectors?
• Which type of adeno-associated viral vector related technologies are presently offered / being developed by the players in this domain?
• Which geographies are the most active in conducting clinical trials related to adeno-associated viral vectors?
• Which partnership models are commonly adopted by industry and non-industry stakeholders?
• Which companies are likely to partner with adeno-associated viral vector and gene therapy product manufacturers?
• What are the different initiatives undertaken by start-ups for the development of adeno-associated viral vectors in the recent past?
• Which factors are likely to influence the decision of manufacturing the adeno-associated viral vector in-house or via outsourcing?
• How is the current and future market opportunity likely to be distributed across key market segments?

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. ADENO-ASSOCIATED VIRAL VECTOR BASED THERAPY: MARKET LANDSCAPE

5. ADENO-ASSOCIATED VIRAL VECTOR MANUFACTURERS: MARKET LANDSCAPE

6. ADENO-ASSOCIATED VIRAL VECTOR MANUFACTURING TECHNOLOGIES: MARKET LANDSCAPE

7. DRUG PROFILES

8. COMPANY PROFILES

8.1. Chapter Overview

8.2. Abeona Therapeutics

8.3 Aldevron (Acquired by Danaher)

8.4 Oxford BioMedica

8.5 Sanofi (CEPiA, Sanofi Pasteur, Genzyme)

8.6. WuXi AppTec

8.7. YPOSKESI

9. COMPANY COMPETITIVENESS ANALYSIS

9.1. Chapter Overview

9.2. Methodology and Key Parameters

9.3. Adeno-Associated Viral Vector Manufacturers: In-house Manufacturers

9.3.1. Players based in North America

9.3.2. Players based in Europe

9.4. Adeno-Associated Viral Vector Manufacturers: Contract Manufacturing Organizations

9.4.1. Players based in North America

9.4.2. Players based in Europe

9.4.3. Players based in Asia-Pacific

9.5. Adeno-Associated Viral Vector Manufacturers: Both In-House and Contract Manufacturing Organizations

9.5.1. Players based in North America

9.5.2. Players based in Europe

9.5.3. Players based in Asia-Pacific

10. TECHNOLOGY COMPETITIVENESS ANALYSIS

11. CLINICAL TRIAL ANALYSIS

12. PARTNERSHIPS AND COLLABORATIONS

13. STRATEGIC PARTNER ANALYSIS

14. PATENT ANALYSIS

15. START-UP HEALTH INDEXING

16. OUTSOURCING: GO / NO-GO FRAMEWORK

17. MARKET SIZING AND OPPORTUNITY ANALYSIS

18. CONCLUDING REMARKS

19. EXECUTIVE INSIGHTS

20. APPENDIX 1: TABULATED DATA

21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

For more information about this report visit https://www.researchandmarkets.com/r/ls4gtp

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900